Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Exceptional clinical leadership in the 21st century demands strong communication skills and the ability to listen to colleagues. Effective leadership necessitates a cultural shift within organisations, fostering openness and innovation.
Catch up on insightful discussions from the expert panel featuring…
Congratulations on the launch of "Every Dose Used-Reducing Wasted Medicines Playbook" co-authored by Deloitte & @YewMaker on behalf of the Sustainable Medicines Partnership. Download the report here.
Attendees
Sponsors and
Exhibitors
Agenda
Webinars
Contact us